On Wednesday, Xencor Inc. (NASDAQ:XNCR) said it is revising its revenue outlook for royalties tied to Ultomiris.The company announced that its licensee, Alexion Pharmaceuticals, Inc., has stated it does not owe additional royalties for Ultomiris (ravulizumab-cwvz) sales in the U.S.AstraZeneca Plc (NYSE:AZN) completed its acquisition of Alexion Pharmaceuticals in July 2021 for approximately $39 billion.Company Seeks ResolutionPrior Royalty ExpectationsXencor previously said that following the issuance of U.S ...